New pill may help prevent breast cancer return in women with certain genes
NCT ID NCT07353437
First seen Jan 22, 2026 · Last updated Apr 25, 2026 · Updated 15 times
Summary
This study tests whether adding the drug fluzoparib to standard treatment can help prevent breast cancer from coming back in women with early-stage breast cancer who have specific gene changes (HRR mutations). About 334 women will be randomly assigned to receive either fluzoparib plus standard care or standard care alone for one year. The main goal is to see if fluzoparib improves the time women stay cancer-free.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.